

The Vice-President of India Visits Bharat Biotech, Emphasises the Importance of Research and Development

Hyderabad, India, 26th April 2024 The Honourable Vice-President of India, Shri. Jagdeep Dhankhar visited Bharat Biotech's facilities at Genome Valley, Hyderabad, which focused on innovation, research & development, and large-scale manufacturing facilities for vaccines. The Vice-President was accompanied by Shri. C. P. Radhakrishnan, the Honourable Governor of the State of Telangana.

The visit commenced with a welcome from Dr. Krishna Ella, Executive Chairman of Bharat Biotech and Mrs. Suchitra Ella, Co-Founder and Managing Director of Bharat Biotech, who expressed gratitude for the Vice-President's interest in the company's mission.

The Vice-President's visit reaffirmed the vital contribution and role of Bharat Biotech in the nation's ongoing immunisation programs and is ready to combat the pandemic.

Soon after reaching the facility, the Vice-President Shri. Jagdeep Dhankhar was briefed in detail about the manufacturing facility, the intricate processes involved in vaccine production, and the company's initiatives to develop new molecules and vaccine candidates to fight neglected diseases that affect the developing world, specifically focused on malaria, cholera, tuberculosis, and chikungunya.

The Vice-President began his tour by planting a medicinal sapling at Bharat Biotech. Shri. **Jagdeep Dhankhar** admired Bharat Biotech's dedication and resilience during unprecedented challenges and said, "I am at a place where people are driven with a passion for research, development and concern for society, Bharat Biotech has not only helped the nation fight the pandemic developing indigenous vaccine, but also contributed immensely in digital penetration," The vice president also urged greater collaboration between industry, academia and support to back more research in all sectors."

In his address, **Dr. Krishna M Ella, Executive Chairman of Bharat Biotech**, thanked the Vice-President for recognising Bharat Biotech's dedication and reaffirmed the company's continued commitment to developing novel vaccines, contributing to national self-reliance goals, and shaping a healthier future. It was a momentous occasion for the company to have the Vice President visit and grace us on world intellectual property day. He highlighted Bharat Biotech continued focus on IP's which resulted in 400 patents".

Mrs. Suchitra Ella, MD of Bharat Biotech, highlighted the company's commitment to public health and its over 25-year journey, as well as the efforts of its workforce. "At Bharat Biotech, we believe that every vaccine produced brings us one step closer to overcoming infectious diseases that affect public health and prevent crises." Mrs. Ella updated the progress of the vaccines in the pipeline and discussed Bharat Biotech's efforts to achieve self-reliance in vaccine discovery.

The Vice-President interacted with the scientists and team leaders and applauded the collective determination to develop novel vaccines and make India self-reliant.



The Vice-President was taken on a virtual tour, offering a glimpse into the inner workings of the production facility. From the state-of-the-art equipment to precise quality control measures, the virtual tour provided a fascinating insight into the meticulous process involved in researching and developing each vaccine dose rolled out from the facility, such as the Rotavirus Vaccine, Typhoid Conjugate Vaccine and Hepatitis Vaccine.

About Bharat Biotech:

Bharat Biotech (BBIL) is a biotech company in Genome Valley, Hyderabad, India. BBIL is a global leader with 145 patents, ~20 vaccines and bio-therapeutics, and registrations in 125 countries. These vaccines were developed through clinical trials in more than 20 countries worldwide and have been published in more than 100 peer-reviewed journals. The company has manufactured and supplied more than 9 billion doses of vaccines globally, saving millions of lives and livelihoods annually.

The company has world-class vaccine and bio-therapeutics research, product development, manufacturing, and distribution facilities. BBIL has developed vaccines for infectious diseases, including Hepatitis B, Pentavalent (DPT+HepB+Hib), Rabies, Typhoid, polio, H1N1 influenza, Japanese Encephalitis (JENVAC®), India's first Rotavirus vaccine, the world's first Typhoid conjugate vaccine, TYPBAR TCV®, novel vaccines for COVID-19 such as COVAXIN® and INCOVACC®. BBIL introduced WHO pre-qualified vaccines, namely BIOPOLIO®, ROTAVAC®, ROTAVAC 5D®, and TYPBAR TCV®, in several countries worldwide.

BBIL has a strong pipeline of innovative vaccines against malaria, cholera, tuberculosis, Para Typhi A, non-typhoidal salmonella, chikungunya, and Zika. The acquisition of Chiron Behring Vaccines has positioned Bharat Biotech as one of the world's largest rabies vaccine manufacturers with CHIRORAB® and INDIRAB®. To learn more about BBIL, visit www.bharatbiotech.com.

Media contact for Bharat Biotech

Sheela Panicker | +91 984 980 9594 | enright@enrightpr.com